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The assay of Complex I activity requires the use of artiikial acceptors, such as short-chain coenzyme Q homologs and analogs, because the 
physiological quinones, such as CoQ,,, are too insoluble in water to be added as substrates to the assay media. The medical interest raised in the 
last years on the pathological changes of Complex I activity has focussed on the requirement of easy reliable assays for its analysis. We have 
undertaken a systematic examination of the assay conditions of Complex I in mitochondrial membranes, using a series of quinones as electron 
acceptors, particularly the coenzyme Q homologs CoQo, CoQl and CoQ,, and the analogs duroquinone and decylubiquinone. Our findings have 
pointed out that the most suitable electron acceptor for the NADH:CoQ reductase assay is the homolog CoQ1. The analog DB, commercially 
available, although yielding a high activity, nevertheless causes some problems for the standardization of the assay conditions. 
NADECoQ oxidoreductase; Coenzyme Q homoiog and analog; Beef heart mitochondria 
NADH:coenzyme Q oxidoreductase (EC 1.6.99.3) or 
Complex I of the mitochondrial respiratory chain cata- 
lyzes the reduction of lipid-soluble coenzyme Q (ubiqui- 
none, CoQ) by water-soluble NADH. Purified Complex 
I has a molecular mass of approximately 700 kDa and 
is now recognized to be an assembly of at least 41 differ- 
ent polypeptides; seven hydrophobic intrinsic mem- 
brane subunits are encoded by the mitochondrial 
genome [I]. Recently the interest in Complex I has in- 
creased also on biomedical grounds, as it was discov- 
ered that some degenerative diseases may be associated 
with genetic or acquired efects of this enzyme, and that 
Complex I defects may be one main result of primary 
somatic mutations of mitochondrial DNA in the ageing 
process [2,3]. This medical interest on the one hand has 
prompted further investigations on the structure and 
genetics of Complex I, and on the other has focussed on 
the requirement of easy reliable assays for its analysis 
for clinical chemistry purposes. 
The physiological electron donor to Complex I is 
NADH and the acceptor is lipid-soluble cndogenous 
cake Q (CoQro in most ma~alian ~t~hondria). 
*Correspon&mg author. Fax: (39) (51) 351217. 
Abbreviations: CoQ,, ubiquinone or coenzyme Q (n = &10 refer to the 
number of isoprenoid units in the lateral chain); DQ, duroquinone; 
DB, 6-decylubiquinone; PB, (i-pentylubiquiuone; BHM, beef heart 
mitochondris; SMP, submitochondrial particles; NASH, nicotin- 
amide adenine dinucleotide, reduced form; PL, phospholipid vesicles. 
Enzyme: NAlXkcm~e Q oxidoreductase EC 1.6.99.3 [Com- 
plex I). 
The assay of Complex I activity requires the use of 
artificial acceptors, because the phy~olo~cal quinones, 
such as CoQ,,, are too insoluble in water to be added 
as substrates to the assay media. The most commonly 
used acceptors are short-chain CoQ homologs (from 
CoQ, up) or analogs as tetramethylbenzoquinone (du-
roquinone, DQ) and analogs having straight saturated 
chains, such as 6-pentyl and 6-decyl ubiquinones (PB 
and DB, respectively) [4-7]. Some of these acceptors 
have been used in assays concerned with mitochondrial 
pathologies, although in most cases the activity of Com- 
plex I has been measured indirectly from NADH oxida- 
tion by cytochrome c or oxygen. Neve~heless the suita- 
bility of some quinone acceptors in the assay of the 
Complex I activity is not clear. The water solubility of 
some acceptors i low and consequently it is difficult o 
reach kinetic saturation during the assay; some ubiqui- 
none homologs behave as Complex I inhibitors f8] and 
the respiratory chain contains quinone redu@on sites 
downstream of the dehydrogena~s [9,10]. T& location 
of the quinone interaction sites is routinely assessed by 
using specific inhibitors of Complex I (as rotenone and 
piericidin A) and Complex III (antimycin A for center 
d and rn~ot~~ol, mucidin, s~~ate~~ and undecyl- 
hydroxydioxo~~othi~ole (UHDBT) for center o) 
[l 11. Nevertheless it was recently found in our labora- 
tory [12] that center o inhibitors, maximally myxo- 
thiazol and stigmatellin, also inhibit Complex I, while 
piericidin A also inhibits center o in Complex III, 
For these reasons we have decided to undertake a
systematic examination ofthe assay conditions of Com- 
plex I in situ in mitochondrial membranes, using a series 
of quinones as electron acceptors, particularly CoQe, 
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CoQ,, CoQ,, DQ and DB (Fig. l), and attempting to 
evaluate their reduction site(s) in the presence of the 
inhibitors antimycin A {center i of the bcr complex) and 
mucidin (center 0). 
2. MATERIALS AND METHODS 
Isoprenoid CoQ homologs (CoQ, and CoQa and CoQO were kind 
gifts from Eisai Co. (Tokyo, Japan). NADHBform, mixed phospho- 
lipids from soybean (~-a phosphatidylchoiine), decylubiquinone (DB) 
and duroquinone (DQ) were purchased from Sigma Chemical Co. (St. 
Louis, MO, USA). The inhibitors antimycin A and rotenone were 
from Sigma Chemical Co. Mucidin was a kind gift from Dr. J. Subik, 
University of Bratislava, Slovakia. All quinones and inhibitors were 
conserved as ethanolic solutions at -20°C in the dark. Quinone con- 
centration was determined spectrophotometrically: CoQ,, L 263 nm, 
E 13.6 mM_’ . cm-‘; CoQ, and CoQ2, 1275 mn, E 13.7 mM-’ * cm-‘; 
DB, a 278 nm, E 14.0 mM-’ . cd; DQ, 1270 mn, E 19.2 mM-’ . cm-‘. 
The inhibitor concentration was determined as previously described 
[13,14]. 
Beef heart mitochondria were obtained by a large-scale procedure 
[I5]. Submitochondrial particles (SMP) were prepared by sonic irradi- 
ation of the frozen and thawed mitochondrial preparation [16] and 
suspended in 0.33 mM sucrose, 25 mM His-HCl, 0.5 mM histidine 
buffer, pH 8.0. All preparations were kept frozen at -80% and frozen 
and thawed 2-3 times before use. It was shown that under these 
~nditions the ~~ea~~ty barrier for NADH is completely lost, as 
demonstrated by lack of further striation by detergents [ 171. Protein 
was evaluated as in [18]. 
NADHCoQ reductase activity was assayed in 50 mM KC% 10 mM 
Tris-HCI, 1 mM EDTA, 2 mM KCN buffer, pH 7.4. Samples were 
diluted to IO-l.5 &ml for SMP and 20-30 @ml for BHM in assay 
medium and incubated for 5 mm without inhibitors or with either 
rotenone (100-200 nmoI/mg protein), antimycin A (lSO-250 nmoI/ 
mg), mucidin (50-75 nmol/mg) and a combination of mucidin and 
antimycin A. Sonicated mixed phospholipids (PL) were added, when 
tested, at different concentrations (between 0.05 and 0.50 mg/ml) in 
the assay medium. NADH was added at 75 FM and acceptors at 
adequate concentration for maximal activity (indicated in the tables). 
Time-course oxidation of NADH was followed in a Sigma-Biochem 
doubl5wavel~~h s~trophotometer equipped with a rapid mixing 
ap~ratus (Cuv-Q-Stir of Helhna) at A 340 minus 380 nm (s 5.5 
mM_’ . cm-‘). 
3. RESULTS 
NADH:CoQ reductase activity has been assayed at 
quasi-saturating concentrations of NADH and of qui- 
none acceptors, previously determined by rate inspec- 
tion at different acceptor concentrations. Fig. 2 shows 
traces of NADH oxidation using CoQr, DB and DQ in 
bovine heart sub~t~ond~~ particles (SMP). A simi- 
lar behavior has been observed in beef heart mitochon- 
dria (BHM). The kinetics are linear for CoQ, and DQ, 
although the rate is more than double with CoQ,, 
whereas DB systematically shows a non-linear behavior 
and CoQ, (not shown) exhibits non-linear kinetics, like 
DB, albeit with lower activity. Table I summarizes the 
NADH:CoQ oxidoreductase activity observed in BHM 
and SMP. The rates are higher in the SMP preparations. 
In spite of their similar hydrophobicity, CoQZ is a 
poorer acceptor in comparison to DB. Under the condi- 
tions of our experiments with all quinone acceptors 
12s 
used, except CoQO, the flow of electrons is physiologi- 
cally channeled through Complex I, as shown by the 
almost total (> 90%) inhibition by rotenone (Table I). 
The non-linear behavior of the more hydrophobic com- 
pounds (DB, CoQ,) may be the result of their low solu- 
bility preventing monomeric dispersion and hence at- 
tainment of the real saturating concentrations; accord- 
ingly, addition of mixed sonicated phospholipids (PL) 
to the assay medium greatly enhances the rate of DB 
and CoQ2 reduction and yields linear kinetics (Table I). 
Nevertheless, phosphoIipids also stimulate activity with 
the other acceptors tudied. The amount of phosphoii~ 
ids added is critical for each quinone acceptor. Particu- 
larly, DB showed a marked dependence on the phos- 
pholipid concentration, with an optimal PL concentra- 
tion for the maximal activity, as shown in Fig. 3, while 
the other acceptors reach a plateau (e.g. CoQJ. 
We have previously confhmed that antimycin A and 
mucidin have little effect on Complex I activity [12]. 
Therefore we have chosen to use antimycin A as a diag- 
nostic of center i inhibition and mu&din to block eleo 
tron transfer to center o. Myxothiazol was discarded 
because it has been confinned to behave as an inhibitor 
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Fig. 1. Chemical structure of the Coenzyme Q homologs CoQ,, CoQ, 
and CoQZ and the analogs duroquinone and decylubiquinone used as 
electron amptots iu the NADHCoQ oxidoreductase assays. 
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Fig. 2. Tie-course oxidation of NADH by the electron acceptors 
duroquinone @Q), decylubiquinone (DB) and Coenxyme Q1 in bo- 
vine heart submitochondrial particles. 
of Complex I, as previously pointed out [12]. The com- 
bination of antimycin A and mucidin represents the so- 
called ‘double kill’ of the bc, Complex, by which no 
electron transfer is possible any more to the & cyto- 
chromes [l 1). Table II shows the effects of these inhib- 
itors on NADH oxidation by the quinone acceptors 
assayed in BHM. The rate of electron transfer in the 
presence of both antimycin A and mucidin may be 
taken as a measure of the real Complex I activity with 
a given quinone acceptor. The results indicate a high 
extent of electron flow to Complex III when CoQo and 
DQ are used, whereas this extent is smaller with the 
other acceptors. Smce the rates with CoQ, and DQ are 
Table I 4. DISCUSSION 
NADIKoQ oxidoreductase activity in beef heart mitochondria 
(BHM) and submitochondrial particles (SMP) with the different ac- 
ceptors and in presence of phospholipids (PL) 
Our study shows, for the first time, a screening of the 
suitability of the most commonly used quinone electron 
acceptors in the assay of NADH:coenzyme Q oxidore- 
ductase. It is generally assumed that these ubiquinone 
homologs and analogs interact with the physiological 
site in place of endogenous CoQ, as derived from the 
rotenone sensitivity. Nevertheless we have shown that 
the issue is much more complex. The water solubility of 
the quinones is the f~damental factor for assessing 
whether kinetic sat~a~on is reached during assay, a 
prerequisite for enzymatic determinations. In this sense, 
the most lipophihc quinones, such as CoQz and DB, 
showed non-linear kinetics. Addition of phospholipids 
to the assay medium notably improved the linearity of 
the reaction, as well as the activity ratio. Nevertheless 
NADH oxidation by DB was highly dependent on the 
amount of phospholipids, reaching a maximum at an 
optimal amount and decaying beyond this, while CoQz 
reached a plateau of maximum activity. 
Sample Acceptor Activity 
(nmol . min-’ 7 mg-‘) 
BHM 
Control +PL 
CoQo 215 371 
:z$ 652 177 878 320
216 302 
399 446 
Rotenone Comments 
sensitivity 
(% inbibition) 
12 Linear 
96 Linear 
91 Linear with PL 
93 Linear 
99 Linear with PL 
SMP CoQO 463 634 17 Linear 
COQI 965 1286 95 Linear 
COQZ 292 583 91 Linear with PL 
DQ 313 487 96 Linear 
DB 727 1282 99 Linear with PL 
Assays were performed at the following acceptor concentrations: 100 
pM CoQO, 50 +iM CoQ,. 30 PM CoQ*, 100 PM DQ and 40 PM DB. 
Protein was 20-3O&ml for BHM and 10-15 &ml for SMP. Activity 
in the presence of phospho~pids (PL) represents the maximal stimula- 
tion rate obtained as follows: 0.10 mg/ml PL for DB, 0.25-0.50 m&l 
for the others in the assay medium. Rotenone was add& at 2.5 ,uM. 
0 0.1 0.2 0.3 0.4 0.5 0.8 
[Phospholipidsl (mg/mlf 
Fig. 3. Effect of phosphohpid amount in the assay medium on the 
NADH:CoQ oxidoreductase activity in submitochondrial particles 
using Coenxyme Q2 and decylubiquinone (DB) as electron acceptors. 
basically low, they appear to be poor acceptors for 
Complex I activity; this is particularly true for CoQO, 
that also has lower sensitivity to rotenone, a specific 
inhibitor of Complex I. 
Some of the quinones tested, such as DQ and CoQz, 
showed a lower rate of NADH oxidation. This fact can 
be inconvenient because activity changes (e.g. in pa- 
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thological studies) might not be revealed if they occur 
at a step which is not rate-limiting in the enzymatic 
reaction. Moreover, CoQ, behaves as an inhibitor of 
Complex I, as has been pointed out previously [8]. In 
fact, NADH oxidation rates were the lowest when this 
homolog was used. This inhibitory effect could explain 
the differences observed when compared with its analog 
DB, which is more hydrophobic [19] and consequently 
might show lower activity. 
On the other hand, some of the quinones used as 
electron acceptors are reduced before and beyond the 
physiological site in the Complex I. NADH oxidation 
by CoQo showed a marked insensitivity to rotenone and 
it was greatly affected by the antimycin A-mucidin 
combination, whereas DQ reduction also showed a 
great dependence on the bc, Complex. The other qui- 
nones showed a lower dependence on this reduction site. 
Studies on the location of the reduction sites for qui- 
nones have been done, mainly concerning the succi- 
nate:CoQ oxidoreductase activity (e.g. [lo]). Only a few 
studies have been carried out on Complex I activity and 
most of them have been done by using myxothiazol as 
inhibitor of the center o of the bc, Complex [20,21]. The 
finding that myxothiazol is a sign&ant inhibitor of 
Complex I too [12] raises doubts about some of the 
interpretations of those results. 
The major points of our work could be summarized 
as follows. CoQ, and DB are the best electron acceptors 
for the study of the NADH:CoQ oxidoreductase activ- 
ity. DB has the advantage that it yields a high real 
Complex I activity and is easy to obtain commercially; 
nevertheless the non-linear kinetics with DB is a prob- 
lem. It can be avoided with the addition of phospholip- 
ids to the assay medium, but it is necessary to standard- 
ize their amount for optimal assay. By contrast, CoQ, 
has been revealed as the best acceptor, yielding the high- 
est rate of Complex I activity, linear kinetics and rela- 
tive independence of the phospholipid concentration. 
On the other hand CoQ, shows a very good linear cor- 
relation between the rate of Complex I activity and the 
amount of protein used for the assay in a wide range of 
concentrations from 2 to 15 &ml of the total mito- 
Table II 
NADH:CoQ oxidoreductase activity in beef heart mitochondria 
(BHM) in presence of the inhibitors of bc, Complex 
Sample Acceptor Residual activity (96) 
Antimycin A Mucidin Both 
BHM CcQo 64 78 47 
CoQ, 80 95 70 
CcQz 82 78 73 
DQ 55 70 40 
DB 75 97 77 
Samples were incubated for 5 min at the following inhibitor concentra- 
tions: 4.6 PM antimycin A and 1.5 PM mucidin. 
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Fig. 4. Effect of protein concentration on the rate of NADH:CoQ, 
reductase activity in submitochondrial particles. 
chondrial protein (Fig. 4) with a detection limit of ca. 
1 nmol NADH oxidized per ml per min. Also, the ana- 
lytical reproducibility using CoQ, as electron acceptor 
is quite good, giving an average value of 0.925 + 0.13 
(n = 8). Nevertheless its application for chemical chem- 
istry purposes is difficult because it is not commercially 
available (at least at the moment). The other quinones 
studied have disadvantages and these must be avoided. 
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